Beijing Konruns Pharmaceutical Co.,Ltd. Stock Price

SHSE:603590 Community·CN¥6.0b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

603590 Share Price Performance

CN¥0

-29.58 (-100.00%)

CN¥0

-29.58 (-100.00%)

CN¥0

Tue, 26 May 26

Share Pricen/a

603590 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet with proven track record.

1 Risk

3 Rewards

View Full Analysis

Beijing Konruns Pharmaceutical Co.,Ltd. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: 1.07
: 89.84%
: 18.38%
: 9.4%

View Full Analysis

About 603590

Founded: 2003
Employees: 793
CEO: Zhanqi Niu
WebsiteView website: www.konruns.cn

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.